Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

The review that pooled the results of 11 studies has found that people started regaining weight two months after stopping the ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

A new report from The Center for Medicine in the Public Interest (CMPI) warns that regulators are failing to stop the illegal ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...